Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Depreciation & Amortization (CF) (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $834000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 28.47% to $834000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 22.31% year-over-year, with the annual reading at $3.3 million for FY2025, 22.31% down from the prior year.
  • Depreciation & Amortization (CF) hit $834000.0 in Q4 2025 for Immunocore Holdings, up from $798000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q4 2024 to a low of $780000.0 in Q2 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $963333.3 across 3 years, with a median of $1.0 million in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 12.98% in 2024 and later decreased 28.47% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2023, then rose by 12.98% to $1.2 million in 2024, then decreased by 28.47% to $834000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IMCR at $834000.0 in Q4 2025, $798000.0 in Q3 2025, and $780000.0 in Q2 2025.